CJC-1295 vs Ipamorelin: GH Secretagogue Pathways Compared

CJC-1295 and Ipamorelin are two of the most-studied growth hormone secretagogues. Though both ultimately stimulate growth hormone release, they work through entirely different receptor pathways — and understanding the difference is essential for researchers designing GH secretagogue studies. Researchers looking to buy peptides UK can find both options available in our shop.

The Two Pathways of GH Release

Growth hormone is released from the pituitary gland under the control of two primary stimulatory pathways:

1. The GHRH pathway — growth hormone releasing hormone, produced by the hypothalamus
2. The ghrelin pathway — ghrelin, produced primarily in the stomach, acting through the ghrelin receptor (GHS-R1a)

These are the two principal mechanisms of endogenous GH release. CJC-1295 and Ipamorelin each target one of these pathways.

CJC-1295: The GHRH Pathway

CJC-1295 is a synthetic analogue of GHRH (growth hormone releasing hormone). It binds and activates the GHRH receptor on the pituitary, amplifying the signal that drives GH release.

Key Characteristics

• Target: GHRH receptor
• Mechanism: Mimics and amplifies natural GHRH signalling
• Duration: Extended duration of action (long half-life)
• Pattern: Sustained GHRH receptor activation

CJC-1295 (No DAC)

The form most commonly used in research is CJC-1295 without DAC (Drug Affinity Complex). This version has a shorter half-life than the DAC variant but produces more natural, pulsatile GH release patterns — which is preferred for research studying physiological GH rhythms.

Ipamorelin: The Ghrelin Pathway

Ipamorelin is a ghrelin receptor agonist (a growth hormone secretagogue). It binds and activates the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus, stimulating GH release through the complementary ghrelin pathway.

Key Characteristics

• Target: Ghrelin receptor (GHS-R1a)
• Mechanism: Mimics ghrelin signalling
• Selectivity: Relatively selective for GH release — does not significantly affect cortisol or prolactin
• Pattern: Pulsatile GH release through the ghrelin pathway

Why Selectivity Matters

Ipamorelin's selectivity for GH release — without significantly affecting cortisol, prolactin, or other hormones — makes it a cleaner research tool than some other ghrelin receptor agonists. This allows researchers to study ghrelin-pathway GH release without confounding hormonal effects.

CJC-1295 vs Ipamorelin: The Key Difference

The simplest way to understand the difference:

• CJC-1295 works through the GHRH pathway — amplifying the brain's primary GH-release signal
• Ipamorelin works through the ghrelin pathway — activating the body's other major GH-release signal

These are complementary pathways, not redundant ones. Each produces a distinct GH-release signal, and the two signals interact in ways that researchers study by activating one or both pathways.

When to Use Each

CJC-1295 Alone

Choose CJC-1295 when your research focuses on:

• GHRH receptor activation and signalling
• The GHRH pathway specifically
• Sustained GH-release signal patterns
• IGF-1 production downstream of GHRH activation

Ipamorelin Alone

Choose Ipamorelin when your research focuses on:

• Ghrelin receptor activation and signalling
• The ghrelin pathway specifically
• Selective GH release without cortisol or prolactin effects
• The ghrelin arm of metabolic and GH research

The CJC/Ipamorelin Blend

For research that studies the combined activation of both pathways, the CJC/Ipamorelin Blend (10mg) contains 5mg CJC-1295 (No DAC) and 5mg Ipamorelin in a single vial.

In research models, combined GHRH and ghrelin receptor activation is associated with:

• Amplified, pulsatile GH release
• Greater total GH output than either pathway alone
• More physiologically representative GH release patterns

Comparison Summary

Feature	CJC-1295	Ipamorelin
Target receptor	GHRH receptor	Ghrelin receptor (GHS-R1a)
Pathway	GHRH	Ghrelin
GH release pattern	Sustained	Pulsatile
Selectivity	GH-specific	GH-specific (minimal cortisol/prolactin effect)
Common form	No DAC	—

Purity and Verification

Both CJC-1295 and Ipamorelin are sensitive to impurities — related peptides or degradation products can interfere with receptor binding and produce confounding effects. As a leading peptide supplier UK, every batch of the CJC/Ipamorelin Blend from HPLC Peps is independently tested by Janoshik at >99% HPLC purity, with Certificates of Analysis published for every batch.

Summary

CJC-1295 and Ipamorelin target different GH-release pathways — GHRH and ghrelin respectively. For research studying a single pathway, choose the appropriate individual compound. For research studying the combined effects of both pathways, the CJC/Ipamorelin Blend provides both in a single vial. Browse the CJC/Ipamorelin Blend or the full GH & Longevity category. See all our comparison guides.